We are live on ! Find out more
FDMT icon

4D Molecular Therapeutics
FDMT

120 hedge funds and large institutions have $151M invested in 4D Molecular Therapeutics in 2025 Q2 according to their latest regulatory filings, with 17 funds opening new positions, 43 increasing their positions, 40 reducing their positions, and 22 closing their positions.

New
Increased
Maintained
Reduced
Closed

16% more call options, than puts

Call options by funds: $171K | Put options by funds: $147K

7% more capital invested

Capital invested by funds: $141M → $151M (+$10.1M)

8% more repeat investments, than reductions

Existing positions increased: 43 | Existing positions reduced: 40

4% less funds holding

Funds holding: 125 → 120 (-5)

5.85% less ownership

Funds ownership: 93.06% → 87.21% (-5.9%)

23% less first-time investments, than exits

New positions opened: 17 | Existing positions closed: 22

Holders
120
Holders Change
-5
Holders Change %
-4%
% of All Funds
1.58%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
17
Increased
43
Reduced
40
Closed
22
Calls
$171K
Puts
$147K
Net Calls
+$24K
Net Calls Change
-$3K

Top Buyers

Rank Fund Capital Flow
1
Federated Hermes
Federated Hermes
Pennsylvania
+$1.47M
2
Two Sigma Advisers
Two Sigma Advisers
New York
+$889K
3
Bank of America
Bank of America
North Carolina
+$699K
4
Royal Bank of Canada
Royal Bank of Canada
Ontario, Canada
+$606K
5
Raymond James Financial
Raymond James Financial
Florida
+$566K

Top Sellers

Rank Fund Capital Flow
1
RG
Redmile Group
California
-$3.11M
2
Morgan Stanley
Morgan Stanley
New York
-$3M
3
VA
VR Adviser
New York
-$2.19M
4
BlackRock
BlackRock
New York
-$1.89M
5
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
Ontario, Canada
-$1.33M
Name Holding Trade Value Shares
Change 		Change in
Stake
BI
1
BVF Inc
California
$17.2M +$239K +68,000 +1%
RCM
2
RA Capital Management
Massachusetts
$16.9M – – –
Goldman Sachs
3
Goldman Sachs
New York
$15.4M -$32.1K -9,130 -0.2%
BlackRock
4
BlackRock
New York
$14.9M -$1.89M -536,397 -12%
Vanguard Group
5
Vanguard Group
Pennsylvania
$10.2M -$73.2K -20,819 -0.8%
NHAS
6
Novo Holdings A/S
Denmark
$7.42M +$176K +50,000 +3%
Janus Henderson Group
7
Janus Henderson Group
United Kingdom
$6.51M -$483K -137,525 -7%
Federated Hermes
8
Federated Hermes
Pennsylvania
$6.19M +$1.47M +417,157 +33%
Millennium Management
9
Millennium Management
New York
$5.5M -$528K -150,263 -9%
State Street
10
State Street
Massachusetts
$3.57M -$232K -65,988 -6%
Morgan Stanley
11
Morgan Stanley
New York
$3.43M -$3M -852,067 -48%
Geode Capital Management
12
Geode Capital Management
Massachusetts
$3.41M -$157K -44,736 -5%
Bank of America
13
Bank of America
North Carolina
$3.33M +$699K +198,762 +28%
JP Morgan Chase
14
JP Morgan Chase
New York
$3.29M +$4.61K +1,311 +0.1%
Two Sigma Advisers
15
Two Sigma Advisers
New York
$2.76M +$889K +253,000 +52%
Assenagon Asset Management
16
Assenagon Asset Management
Luxembourg
$2.41M -$7.49K -2,131 -0.3%
Two Sigma Investments
17
Two Sigma Investments
New York
$1.97M +$245K +69,706 +15%
ACH
18
ArrowMark Colorado Holdings
Colorado
$1.91M -$44.5K -12,656 -2%
Raymond James Financial
19
Raymond James Financial
Florida
$1.69M +$566K +161,091 +55%
Acadian Asset Management
20
Acadian Asset Management
Massachusetts
$1.23M -$246K -70,015 -17%
Northern Trust
21
Northern Trust
Illinois
$1.22M -$183K -51,945 -14%
PLC
22
Peapod Lane Capital
New York
$1.18M +$431K +122,684 +63%
DekaBank Deutsche Girozentrale
23
DekaBank Deutsche Girozentrale
Germany
$1.17M – – –
AC
24
Armistice Capital
New York
$1.11M – – –
Charles Schwab
25
Charles Schwab
California
$1.09M +$43.1K +12,260 +4%
1
2 3 4 5

FDMT Hedge Fund Activity: Q2 2025 in Review

120 of the 7,595 institutional investors tracked by Wall St. Rank reported a position in 4D Molecular Therapeutics (FDMT) for Q2 2025, worth a combined $151M — up 7.2% from $141M a quarter earlier.

Sellers outnumbered buyers: 22 funds closed out of FDMT and 17 opened new positions — a net loss of 5 holders — while 40 trimmed existing stakes and 43 added.

The largest buyer was Federated Hermes, adding an estimated $1.47M. The largest seller was Redmile Group, cutting an estimated $3.11M.

  • 120 institutional investors held 4D Molecular Therapeutics (FDMT) as of Q2 2025, down from 125 in Q1 2025.
  • Funds reported $151M of 4D Molecular Therapeutics stock for Q2 2025, up 7.2% quarter-over-quarter.
  • 17 funds opened new 4D Molecular Therapeutics positions in Q2 2025 and 22 closed out, a net change of -5 holders.
  • The largest 4D Molecular Therapeutics buyer in Q2 2025 was Federated Hermes, an estimated $1.47M added.
  • The largest 4D Molecular Therapeutics seller in Q2 2025 was Redmile Group, an estimated $3.11M sold.

Based on aggregated 13F filings for Q2 2025.